Untargeted metabolomics approach to discriminate mistletoe commercial products - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Scientific Reports Année : 2021

Untargeted metabolomics approach to discriminate mistletoe commercial products

Cécile Vanhaverbeke
  • Fonction : Auteur
David Touboul
Nicolas Elie
Martine Prévost
  • Fonction : Auteur
Cécile Meunier
  • Fonction : Auteur
Sylvie Michelland
  • Fonction : Auteur
Valérie Cunin
  • Fonction : Auteur
Ling Ma
  • Fonction : Auteur
David Vermijlen
  • Fonction : Auteur
Cédric Delporte
  • Fonction : Auteur
Stéphanie Pochet
  • Fonction : Auteur
Audrey Le Gouellec
  • Fonction : Auteur
Michel Sève
  • Fonction : Auteur
Pierre van Antwerpen
  • Fonction : Auteur
Florence Souard
  • Fonction : Auteur

Résumé

Abstract Mistletoe ( Viscum album L.) is used in German-speaking European countries in the field of integrative oncology linking conventional and complementary medicine therapies to improve quality of life. Various companies sell extracts, fermented or not, for injection by subcutaneous or intra-tumoral route with a regulatory status of anthroposophic medicinal products (European Medicinal Agency (EMA) assessment status). These companies as well as anthroposophical physicians argue that complex matrices composed of many molecules in mixture are necessary for activity and that the host tree of the mistletoe parasitic plant is the main determining factor for this matrix composition. The critical point is that parenteral devices of European mistletoe extracts do not have a standard chemical composition regulated by EMA quality guidelines, because they are not drugs, regulatory speaking. However, the mechanism of mistletoe’s anticancer activity and its effectiveness in treating and supporting cancer patients are not fully understood. Because of this lack of transparency and knowledge regarding the matrix chemical composition, we undertook an untargeted metabolomics study of several mistletoe extracts to explore and compare their fingerprints by LC-(HR)MS(/MS) and 1 H-NMR. Unexpectedly, we showed that the composition was primarily driven by the manufacturer/preparation method rather than the different host trees. This differential composition may cause differences in immunostimulating and anti-cancer activities of the different commercially available mistletoe extracts as illustrated by structure–activity relationships based on LC–MS/MS and 1 H-NMR identifications completed by docking experiments. In conclusion, in order to move towards an evidence-based medicine use of mistletoe, it is a priority to bring rigor and quality, chemically speaking.
Fichier principal
Vignette du fichier
s41598-021-93255-z.pdf (5.64 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03322678 , version 1 (14-10-2021)

Identifiants

Citer

Cécile Vanhaverbeke, David Touboul, Nicolas Elie, Martine Prévost, Cécile Meunier, et al.. Untargeted metabolomics approach to discriminate mistletoe commercial products. Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-93255-z⟩. ⟨hal-03322678⟩
17 Consultations
31 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More